La chaîne d'options affiche les données clés des options sur actions de ATI Physical Therapy à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour ATI Physical Therapy..

ATI Physical Therapy (OTC:ATIP) Stock, Chaîne d'Options

ATI Physical Therapy

ATI Physical Therapy Inc is a recognized outpatient physical therapy provider in the United States specializing in outpatient rehabilitation and adjacent healthcare services. It offer a variety of services within the clinics, including physical therapy to treat spine, shoulder, knee and neck injuries or pain; work injury rehabilitation services, including work conditioning and work hardening; hand therapy; and other specialized treatment services.

ATI PHYSICAL THERAPY A by ATI Physical Therapy, Inc.

ATI Physical Therapy Inc

ATI Physical Therapy Inc Warrants (10/08/2027)

Spyre Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced Spyre has been added to the Nasdaq Biotechnology Index (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBI#NASDAQ">NBI</a>), effective prior to market open, Monday, December 23, 2024.

News

SYRE

Spyre Therapeutics Added To The Nasdaq Biotechnology Index, Effective Prior To Market Open, December 23, 2024.

WIIM

Organigram shares are trading higher after the company reported better-than-expected Q4 financial results.

The 2024 U.S. elections didn't just reshape Washington—they reignited <a href="https://www.benzinga.com/crypto">the cryptocurrency market</a>, dominated by Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>). 
Since November, cryptocurrencies have rallied an impressive 65%, and according to JPMorgan analyst Kenneth B. Worthington, this surge is less about Bitcoin's volatility and more about the promise of regulatory clarity under the incoming Donald Trump administration.
<h2 class="wp-block-heading">From Chaos To Clarity</h2>
The industry's long cry for regulatory guardrails may finally be answered. Worthington points out that Trump's presidency brings a crypto-friendly tone to Washington, positioning the digital asset space for a more legitimate future. The president-elect's pro-crypto Congress and key appointments signal a new era where the focus shifts to defining market structures and clarifying which agencies—SEC or CFTC—will call the shots.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42545419/bitcoin-ethereum-dogecoin-stay-muted-before-feds-interest-rate-decision-analyst-says-btc-in-parabolic-phase-reveals-its-duration">Bitcoin, Ethereum, Dogecoin Stay Muted Before Fed&#8217;s Interest Rate Decision: Analyst Says BTC In Parabolic Phase, Reveals Its Duration</a>
Yet, don't expect fireworks just yet. While optimism runs high, actual regulatory reforms are at least 9-12 months away. From SEC and CFTC chair confirmations to rule-making processes, it's a marathon, not a sprint. 
The most immediate impact? 
FAQs and guidance provide the market with a quick dose of clarity, even as Congress wrestles with permanent legislation, the analyst said.
<h2 class="wp-block-heading">Who's Leading The Charge?</h2>
One major piece of the puzzle remains missing: the CFTC chair nomination. 
This role will likely influence the regulation of Bitcoin and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), two pillars of the crypto world. 
Meanwhile, the industry eagerly awaits to see how the SEC and FDIC might ease traditional finance's entry into crypto. Without some semblance of guidance, even the most pro-crypto stance won't move the needle for banks and brokers, according to Worthington.
<h2 class="wp-block-heading">A Glimpse Into The Future</h2>
What does a more transparent crypto ecosystem look like? 
For starters, exchanges like Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Robinhood Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) are already expanding their offerings, onboarding altcoins, and exploring auxiliary services like staking. 
Traditional finance players like Charles Schwab Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) and BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) are also eyeing their next moves, with the latter pushing for Bitcoin allocations in institutional portfolios, the analyst notes.
The bottom line? 
Regulatory clarity could transform crypto from a speculative playground to a cornerstone of financial innovation. With the Trump administration setting a bullish tone, the crypto market might finally have the chance to break free from its regulatory limbo—and investors are paying attention.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42547334/the-new-gold-seasoned-investor-ross-gerber-spots-a-pot-of-bitcoin-at-the-end-of-the-rainbow">The New Gold? Seasoned Investor Ross Gerber Spots A &#8216;Pot Of Bitcoin&#8217; At The End Of The Rainbow</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

Markets

Trading Ideas

$BTC

$ETH

COIN

HOOD

SCHW

Trump Era Will Unlock Crypto Market With Regulatory Clarity, Says Analyst

RZLV

Rezolve AI shares are trading higher after Northland Capital Markets initiated coverage on the stock with an Outperform rating and announced a $5 price target.

Morgan Stanley analyst Meta Marshall maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Equal-Weight and raises the price target from $38 to $40.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on RingCentral, Raises Price Target to $40

CARA

Cara Therapeutics shares are trading lower after the company announced it entered into an all-stock merger with Tvardi Therapeutics.

Biotech

General

SCYX

SCYNEXIS Initiates Dosing In Phase 1 TrialOof SCY-247 For Invasive Fungal Infections

Three-Year Agreement Expected to Generate more than $0.5million in Revenue, and Covers France and French Regions
France is the Second-Largest Fitness Market in the EU
AUSTIN, TX / ACCESSWIRE / December 18, 2024 / Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) ("TRNR" or the "Company"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced it secured exclusive distribution in Metropolitan France and French Regions with French training and equipment brand Planet Fitness SAS. The three-year agreement also includes a minimum commitment of 162 CLMBR units, which is expected to generate more than $0.5 million in revenue.

Contracts

Global

TRNR

Interactive Strength Secures 162 Unit CLMBR Commitment And Signs Exclusive Distribution Agreement With Planet Fitness SAS For France; 3-Year Agreement Expected To Generate More Than $500K In Revenue, And Covers France And French Regions

Morgan Stanley analyst Meta Marshall maintains Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) with a Equal-Weight and raises the price target from $86 to $96.

Morgan Stanley Maintains Equal-Weight on Zoom Communications, Raises Price Target to $96

HOLX

Hologic Entered Agreement With The CDC To Develop Analyte Specific Reagents  Of Tests To Aid In H5N1 Bird Flu Detection

Morgan Stanley analyst Lauren Lieberman maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Equal-Weight and raises the price target from $40 to $46.

FIVN

Morgan Stanley Maintains Equal-Weight on Five9, Raises Price Target to $46

Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A
This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A and SCN8A DEEs
Praxis plans to initiate an all-DEE trial (EMERALD), inclusive of Dravet syndrome, in 1H2025
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=bKqvqDp4-w_R5X1AHVJRq6zSjIigPlsE0IYik8gbdCjYOVuQvIUvjafzi8W2ZX38SV6M0BFYnS8d0ZILDxmoIlWXu7BHcvwcnhWxwO_chVM=">Praxis Precision Medicines</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for relutrigine in Dravet syndrome.

PRAX

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted For Relutrigine In Dravet Syndrome; Praxis Plans To Initiate An All-DEE Trial (EMERALD), Inclusive Of Dravet Syndrome, In 1H2025

Guidance

Textron Expects Inventory Valuation Charge To Reduce Adjusted EPS For 2024 By Approximately $0.12 To $0.16

CGTX

Cognition Therapeutics shares are trading higher after the company announced topline results which met its primary endpoint of safety and tolerability from its exploratory Phase 2 SHIMMER study.

RNAZ

TransCode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Prelim. Results From First Cohort In Phase 1 TTX-MC138 Clinical Trial; Showed No Significant Safety Or Dose Limiting Toxicities In Cohort 2, Says The Dose Administered To The Third Cohort Will Be Approximately Double The Dose Administered To The Second Cohort

Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lithium Sparing Treatment for Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive Disorder and Post-Traumatic Stress Disorder
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alzamend.com%2F&amp;esheet=54168496&amp;newsitemid=20241218800562&amp;lan=en-US&amp;anchor=Alzamend+Neuro%2C+Inc.&amp;index=1&amp;md5=be512c5550eaad892edeafce0b331a2b">Alzamend Neuro, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced it will have a poster presentation at the Society of Toxicology ("SOT") Annual Meeting and ToxExpo, being held from March 16-20, 2025, in Orlando, Florida.

ALZN

Alzamend Neuro To Present Non-Clinical Data Update On Pharmacokinetics Of AL001, A Lithium Salicylate/L-Proline Co-crystal, As A Potentially Beneficial Lithium Sparing Treatment For Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive Disorder And Post-Traumatic Stress Disorder At The Society Of Toxicology 2025 Annual Meeting And ToxExpo

Total pretax special charges related to the 2023 restructuring plan are now expected to increase from the previously announced range of $165 million to $170 million to a range of $190 million to $205 million. The increased charges of $25 million to $35 million are related to contract termination costs associated with the powersports production pause. These charges will be recorded in the fourth quarter of 2024, with additional cash outlays of $25 million to $35 million expected primarily in the first half of 2025. &nbsp;

Textron Approves Additional Actions At Industrial Segment Under 2023 Restructuring Plan

PLRZ

PolyRizon shares are trading higher after the company announced it secured a GMP partnership with Eurofins CDO Amatsiaquitaine.

CRVS

Corvus Pharmaceuticals shares are trading lower. The company announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.

Morgan Stanley analyst James Faucette maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) with a Underweight and raises the price target from $60 to $65.

Morgan Stanley Maintains Underweight on Block, Raises Price Target to $65

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ATI Physical Therapy (NYSE:<a href="https://investorplace.com/stock-quotes/atip-stock-quote/">ATIP</a>) just reported results for the second quarter of 2024.<ul><li>ATI Physical Therapy reported earnings per share of -$2.43. This was above the analyst estimate for EPS of -$2.63.</li><li>The company reported revenue of $188.11 million.</li><li>This was 0.99% worse than the analyst estimate for revenue of $190.00 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/atip-stock-earnings-ati-physical-therapy-for-q2-of-2024/">ATIP Stock Earnings: ATI Physical Therapy Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ATIP Stock Earnings: ATI Physical Therapy Beats EPS, Misses Revenue for Q2 2024

ATI Physical Therapy, Inc. (ATIP) Q2 2024 Earnings Call Transcript

In a report released today, Bill Sutherland from Benchmark Co. maintained a Hold rating on ATI Physical Therapy (ATIP – Research Report). The compa...

ATI Physical Therapy (ATIP) Gets a Hold from Benchmark Co.

ATI Physical Therapy, Inc. (ATIP) Q3 2024 Earnings Call Transcript

Ati Physical Therapy, Inc. ( ($ATIP) ) has released its Q3 earnings. Here is a breakdown of the information Ati Physical Therapy, Inc. presented to...

ATI Physical Therapy Q3 2024 Financial Performance and Outlook

14:29 EST ATI Physical Therapy (ATIP) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, marke...

ATI Physical Therapy trading halted, volatility trading pause

14:34 EST ATI Physical Therapy (ATIP) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...

ATI Physical Therapy trading resumes

The NYSE announced that the staff of NYSE Regulation has determined to commence proceedings to delist the Class A common stock of ATI Physical Ther...

NYSE to begin proceedings to delist common stock of ATI Physical Therapy

The latest announcement is out from ATI Physical Therapy ( ($ATIP) ). ATI Physical Therapy, Inc. is facing delisting from the New York Stock Exchan...

ATI Physical Therapy Faces Delisting and Market Shift

ATI Physical Therapy receives delisting notice from NYSE

ATIP

ATIPW

Press Releases

ATI PHYSICAL THERAPY RECOGNIZED AS A GREAT PLACE TO WORK® FOR 2024

ATI Physical Therapy Provides Settlement Notice

Legal

Pomerantz LLP and Levi & Korsinsky, LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Fortress Value Acquisition Corp. II ("FVAC") or ATI Physical Therapy, Inc. Common Stock or Certain Holders of FVAC Common Stock

ATI Physical Therapy to Announce Second Quarter 2024 Financial Results

Earnings

ATI Physical Therapy Reports Second Quarter 2024 Results

ATI Physical Therapy to Announce Third Quarter 2024 Financial Results

ATI Physical Therapy Reports Third Quarter 2024 Results

For 5th Consecutive Year, ATI Physical Therapy Achieves 'Exceptional' Rating In Patient Quality from the Center For Medicare and Medicaid Services (MIPS)

ATI Physical Therapy Receives Delisting Notice From the New York Stock Exchange

Offerings

Small Cap

ATI Physical Therapy Announces Commencement of Tender Offer to Purchase Up to 1,650,000 Shares of its Class A Common Stock at a Purchase Price of $2.85 per Share

Comments

ATI Physical Therapy

ATI Physical Therapy (ATIP) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL